Thermodynamic property measurements in reflected shock air plasmas at 12,000 - 16,000 K

Reflected shock air plasma thermodynamic properties at 12,000 to 16,000 deg

Mechanical Properties and Biological Responses of Bioactive Glass Ceramics Processed using Indirect SLS

This paper will report on research which aims to generate bone replacement components by processing bioactive glass-ceramic powders using indirect selective laser sintering. The indirect SLS route has been chosen as it offers the ability to tailor the shape of the implant to the implantation site, and two bioactive glass ceramic materials have been processed through this route: apatite-mullite and apatite-wollostanite. The results of bend tests, to investigate mechanical properties, and in vitro and in vivo experiments to investigate biological responses of the materials will be reported, and the suitability of completed components for implant will be assessed.Mechanical Engineerin

Chemical abundance study of two strongly s-process enriched post-AGB stars in the LMC: J051213.81-693537.1 and J051848.86-700246.9

Context: This paper is part of a larger project in which we study the chemical abundances of extra-galactic post-AGB stars with the ultimate goal of improving our knowledge of the poorly understood AGB third dredge-up mixing processes and s-process nucleosynthesis. Aims: In this paper, we study two carefully selected post-AGB stars in the LMC. The combination of favourable atmospheric parameters for detailed abundance studies and their known distances make these objects ideal probes of the internal AGB third dredge-up and s-process nucleosynthesis in that they provide observational constraints for theoretical AGB models. Methods: We use high-resolution optical UVES spectra to determine accurate stellar parameters and perform detailed elemental abundance studies. Additionally, we use available photometric data to construct SEDs for reddening and luminosity determinations. We then estimate initial masses from theoretical post-AGB tracks. Results: Both stars show extreme s-process enrichment associated with relatively low C/O ratios of about 1.3. We could only derive upper limits of the lead (Pb) abundance which indicate no strong Pb overabundances with respect to other s-elements. Comparison with theoretical post-AGB evolutionary tracks in the HR-diagram reveals that both stars have low initial masses between 1.0 and 1.5 Msun. Conclusion: This study adds to the results obtained so far on a very limited number of s-process enriched post-AGB stars in the Magellanic Clouds. We find an increasing discrepancy between observed and predicted Pb abundances towards lower metallicities for all studied Magellanic Cloud post-AGB stars found so far, as well as moderate C/O ratios. We find that all s-process rich post-AGB stars in the LMC and SMC studied so far, cluster in the same region of the HR-diagram and are associated with low-mass stars with a low metallicity on average.Comment: 11 pages, 14 figure

Chemical abundance study of two strongly s-process enriched post-AGB stars in the LMC: J051213.81-693537.1 and J051848.86-700246.9

Context: This paper is part of a larger project in which we study the chemical abundances of extra-galactic post-AGB stars with the ultimate goal of improving our knowledge of the poorly understood AGB third dredge-up mixing processes and s-process nucleosynthesis. Aims: In this paper, we study two carefully selected post-AGB stars in the LMC. The combination of favourable atmospheric parameters for detailed abundance studies and their known distances make these objects ideal probes of the internal AGB third dredge-up and s-process nucleosynthesis in that they provide observational constraints for theoretical AGB models. Methods: We use high-resolution optical UVES spectra to determine accurate stellar parameters and perform detailed elemental abundance studies. Additionally, we use available photometric data to construct SEDs for reddening and luminosity determinations. We then estimate initial masses from theoretical post-AGB tracks. Results: Both stars show extreme s-process enrichment associated with relatively low C/O ratios of about 1.3. We could only derive upper limits of the lead (Pb) abundance which indicate no strong Pb overabundances with respect to other s-elements. Comparison with theoretical post-AGB evolutionary tracks in the HR-diagram reveals that both stars have low initial masses between 1.0 and 1.5 Msun. Conclusion: This study adds to the results obtained so far on a very limited number of s-process enriched post-AGB stars in the Magellanic Clouds. We find an increasing discrepancy between observed and predicted Pb abundances towards lower metallicities for all studied Magellanic Cloud post-AGB stars found so far, as well as moderate C/O ratios. We find that all s-process rich post-AGB stars in the LMC and SMC studied so far, cluster in the same region of the HR-diagram and are associated with low-mass stars with a low metallicity on average.Comment: 11 pages, 14 figure

Theoretical and experimental investigation of supersonic aerodynamic characteristics of a twin-fuselage concept

A theoretical and experimental investigation has been conducted to evaluate the fundamental supersonic aerodynamic characteristics of a generic twin-body model at a Mach number of 2.70. Results show that existing aerodynamic prediction methods are adequate for making preliminary aerodynamic estimates

Comparison of Allen Carr's Easyway programme with a specialist behavioural and pharmacological smoking cessation support service: a randomized controlled trial.

BACKGROUND AND AIMS: A combination of behavioural and pharmacological support is judged to be the optimal approach for assisting smoking cessation. Allen Carr's Easyway (ACE) is a single-session pharmacotherapy-free programme that has been in operation internationally for 38 years. We compared the effectiveness of ACE with specialist behavioural and pharmacological support delivered to the national standard in England. DESIGN: A two-arm, parallel-group, single-blind, randomized controlled trial. SETTING: London, UK, between February 2017 and May 2018. PARTICIPANTS: A total of 620 participants (310 in ACE and 310 in the combined behavioural and pharmacological support condition) were included in the analysis. Adult (≥ 18 years) smokers wanting to quit were randomized in a 1 : 1 ratio. Mean age for the total sample was 40.8 years, with 53.4% being male. Participant baseline characteristics (ethnicity, educational level, number of previous quit attempts, nicotine dependence) were evenly balanced between treatment groups. INTERVENTION AND COMPARATOR: The intervention was the ACE method of stopping smoking. This centres on a 4.5-6-hour session of group-based support, alongside subsequent text messages and top-up sessions if needed. It aims to make it easy to stop smoking by convincing smokers that smoking provides no benefits for them. The comparator was a specialist stop smoking service (SSS) providing behavioural and pharmacological support in accordance with national standards. MEASUREMENTS: The primary outcome was self-reported continuous abstinence for 26 weeks from the quit/quit re-set date verified by exhaled breath carbon monoxide measurement < 10 parts per million (p.p.m.). Primary analysis was by intention to treat. Secondary outcomes were: use of pharmacotherapy, adverse events and continuous abstinence up to 4 and 12 weeks. FINDINGS: A total of 468 participants attended treatment (255 ACE versus 213 SSS, P < 0.05). Of those who did attend treatment, 100 completed 6-month measures (23.7% ACE versus 20.7% SSS). Continuous abstinence to 26 weeks was 19.4% (60 of 310) in the ACE intervention and 14.8% (46 of 310) in the SSS intervention [risk difference for ACE versus SSS 4.5% (95% confidence interval (CI) = -1.4 to 10.4%, odds ratio (OR) = 1.38)]. The Bayes factor for superiority of the ACE condition was 1.24. CONCLUSION: There was no clear evidence of a difference in the efficacies of the Allen Carr's Easyway (ACE) and specialist smoking cessation support involving behavioural support and pharmacotherapy